AtlasOther conditionsBlindness and vision loss

Refraction disorders

4Curable or preventable in mostAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

What's being tested now

2000: 1 trials started2001: 1 trials started2003: 1 trials started2005: 1 trials started2009: 1 trials started2010: 1 trials started2011: 1 trials started2014: 2 trials started2015: 2 trials started2016: 3 trials started2017: 7 trials started2018: 2 trials started2019: 5 trials started2020: 6 trials started2021: 9 trials started2022: 12 trials started2023: 16 trials started2024: 35 trials started2025: 52 trials started2026: 63 trials started200020102020202663

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 213 active Amblyopia trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.